Remove Business Model Remove Ethics Remove Marketing Remove Pharmaceuticals
article thumbnail

Big Pharma's Hidden Business Model and How Your Company Funds It

Harvard Business Review

The study assembles considerable evidence about the hidden business model of major pharmaceutical companies: to devote most of their research budget to developing hundreds of drugs that provide few if any advantages over existing drugs and then market them heavily to doctors and patients. At Harvard's Edmond J.

article thumbnail

How Pharma Can Fix Its Reputation and Its Business at the Same Time

Harvard Business Review

The business model of research-based pharmaceutical companies is under significant pressure. One antidote to these problems is to transform “access to medicine” from a relentless activist slogan to a fully-fledged business strategy. citizens than pharmaceuticals (the sector’s worst showing in 16 years).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Introducing 100 Coaches: Pay It Forward Champions

Marshall Goldsmith

Lead author of Business Model Generation and Value Proposition Design , which sold over one million copies in 37 languages. Deepa Prahalad – Focused on design and emerging markets. Advisor and Speaker at Dartmouth’s Tuck School of Business. Telisa Yancy – Chief Marketing Officer at American Family Insurance.

article thumbnail

How Merck Is Trying to Keep Disrupters at Bay

Harvard Business Review

Pharmaceutical companies, buffeted by regulatory changes, new drug technologies that alter entry barriers and competition, price pressures, and an estimated 300,000 job cuts since 2000, seem to fit the popular narrative of large organizations unable to deal with disruptive forces. Experimentation is vital.